Scholar Rock
SRRK | NASDAQ
$44.54
+$1.34 (+3.09%)
At close: Nov 16, 2026, 4:00 PM ET
$44.54
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Scholar Rock Company Profile
Company profile explainedCompany Profile
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| David L. Hallal | Chief Executive Officer & Chairman of the Board |
| Robert Keith Woods | Chief Operating Officer |
| Akshay Krishnadas Vaishnaw | President of R&D, Member of Scientific Advisory Board and Director |
| Caryn Parlavecchio | Chief Human Resources Officer |
| Erin Moore | Interim Principal Financial & Accounting Officer |
| Junlin | General Counsel & Corporate Secretary |
| Lisa Wyman | Chief Technical & Quality Officer |
| Mo Qatanani | Chief Scientific Officer |
| Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations |
| Vikas Sinha | CFO & Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 424B5 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
Scholar Rock
| Country | United States |
| IPO Date | May 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 289 |
| CEO | David L. Hallal |
Contact Details
301 Binney Street Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | SRRK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001727196 |
| CUSIP Number | 80706P103 |
| ISIN Number | US80706P1030 |
| SIC Code | 2836 |
Recent News
- 13 hours ago / seekingalpha.comScholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript
- 6 days ago / marketbeat.comWhat Scholar Rock (SRRK) Said on Its Q3 Earnings Call
- 6 days ago / seekingalpha.comScholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
- 6 days ago / zacks.comScholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
- 2 months ago / seekingalpha.comScholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
- 2 months ago / seekingalpha.comScholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
- 2 months ago / benzinga.comScholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
- 2 months ago / reuters.comScholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
- 2 months ago / benzinga.comWhy Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
- 2 months ago / businesswire.comScholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Add to Watchlist
Select watchlists to add or remove SRRK